Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Advancing Bio-purification of Anti-cancer Therapeutic Peptides via Crystallization using Surface Modified Heteronucleants

Descrizione del progetto

Rendere le terapie basate sui peptidi più accessibili e convenienti

I peptidi sono piccole molecole che stanno emergendo come farmaci potenti per il trattamento di tumori e disturbi metabolici, in quanto sono altamente specifici, facili da modificare e biocompatibili. Tuttavia, la loro purificazione è costosa e comporta sprechi. Con il supporto del programma di azioni Marie Skłodowska-Curie, il progetto PetalPure svilupperà un processo di purificazione basato sulla cristallizzazione utilizzando eteronucleanti modificati in superficie per migliorare la capacità di cristallizzazione di questi peptidi difficili. Il metodo proposto fornisce un’alternativa più economica alla cromatografia, riducendo l’uso di solventi e la necessità di resine costose. Rendendo la produzione di peptidi più efficiente e sostenibile, PetalPure intende migliorare l’accesso a trattamenti accessibili e salvavita.

Obiettivo

Peptides are emerging as next generation therapeutics with a promise of treating cancers and metabolic disorders. This is due to their high specificity, precise targeting, small size, ease of modification, and excellent biocompatibility. Despite the acceleration of peptide drug discovery with >800 drugs in clinical trials, the separation and purification processes remain a challenge, requiring sustainable downstream processing. Thus, there is a need for more efficient purification methods to keep pace with peptide-based drug advancements. PetalPure introduces an innovative crystallization-based purification process using surface-modified heteronucleants to enhance the crystallizability of challenging anti-cancer peptides. This multidisciplinary project involves developing solubility models, size-based peptide classification, heteronucleant selection and modification, crystallization process design, and experimental frameworks for broader application. PetalPure aims to provide a more affordable alternative to chromatographic separation, eliminating the need for expensive resins and reducing solvent consumption and waste, in line with the Sustainable Development Goal (SDG) of Responsible Consumption and Production. Additionally, it will lower the time and cost of peptide manufacturing, facilitating wider access to affordable and effective healthcare, contributing to the SDG of Good Health and Well-being. Prof. Heng, with his extensive experience in biopharmaceutical manufacturing and being a leader in peptide crystallization, is an ideal supervisor for this project. Imperial, with its research excellence and experience with MSCA postdoctoral fellows, will offer a supportive environment for PetalPure. This project will play a pivotal role in making me a leading academic by allowing high-impact research, training on teaching, supervision, and other transferable skills as well as long-term collaboration opportunities with pharmaceutical industry and academics.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-MSCA-2024-PF-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
Contributo netto dell'UE
€ 260 347,92
Indirizzo
SOUTH KENSINGTON CAMPUS EXHIBITION ROAD
SW7 2AZ London
Regno Unito
Regione
London Inner London — West Westminster
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato